InsiderTrades.com logo

Kenneth Cunningham Biography and Net Worth

Director of Verona Pharma PLC American Depositary Share
  • Phone
  • Email
  • Website


Dr Cunningham has served as a Non-Executive Director on our board of directors since September 2015.

Dr Cunningham has over 30 years of experience in the pharmaceutical industry including leadership roles at several companies focused on developing respiratory medicines. He serves as Non-Executive Chairperson of the board of directors of Medherant. Between 2006 and 2010, he was at SkyePharma (now part of Vectura Group), initially as Chief Operating Officer and subsequently as CEO where he was involved in the late-stage development of flutiform for asthma. Previously, he was CEO of Arakis, where he was involved in the early clinical development of glcopyrronium bromide, which is now marketed as Seebri for chronic obstructive pulmonary disease. Dr Cunningham received a degree in medicine from St. Mary’s, Imperial College, London University.

What is Kenneth Cunningham's net worth?

The estimated net worth of Kenneth Cunningham is at least $8.53 million as of August 1st, 2025. Dr. Cunningham owns 79,776 shares of Verona Pharma PLC American Depositary Share stock worth more than $8,528,852 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Cunningham may own. Learn More about Kenneth Cunningham's net worth.

How do I contact Kenneth Cunningham?

The corporate mailing address for Dr. Cunningham and other Verona Pharma PLC American Depositary Share executives is 3 MORE LONDON RIVERSIDE, LONDON X0, SE1 2RE. Verona Pharma PLC American Depositary Share can also be reached via phone at 011-44-0-2032834200 and via email at [email protected]. Learn More on Kenneth Cunningham's contact information.

Has Kenneth Cunningham been buying or selling shares of Verona Pharma PLC American Depositary Share?

Kenneth Cunningham has not been actively trading shares of Verona Pharma PLC American Depositary Share within the last three months. Most recently, Kenneth Cunningham sold 10,808 shares of the business's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a transaction totalling $142,017.12. Following the completion of the sale, the director now directly owns 79,776 shares of the company's stock, valued at $1,048,256.64. Learn More on Kenneth Cunningham's trading history.

Who are Verona Pharma PLC American Depositary Share's active insiders?

Verona Pharma PLC American Depositary Share's insider roster includes Christina Ackermann (Director), Michael Austwick (Director), James Brady (Director), Kenneth Cunningham (Director), Lisa Deschamps (Director), David Ebsworth (Director), Martin Edwards (Director), Patrick Finn (Insider), Andrew Fisher (General Counsel), Mark Hahn (CFO), Claire Poll (General Counsel), Kathleen Rickard (Insider), Mahendra Shah (Director), Vikas Sinha (Director), Anders Ullman (Director), and David Zaccardelli (CEO). Learn More on Verona Pharma PLC American Depositary Share's active insiders.

Are insiders buying or selling shares of Verona Pharma PLC American Depositary Share?

In the last year, insiders at the sold shares 30 times. They sold a total of 2,932,176 shares worth more than $29,558,114.16. The most recent insider tranaction occured on August, 1st when Director Kenneth Cunningham sold 10,808 shares worth more than $142,017.12. Insiders at Verona Pharma PLC American Depositary Share own 4.8% of the company. Learn More about insider trades at Verona Pharma PLC American Depositary Share.

Information on this page was last updated on 8/1/2025.

Kenneth Cunningham Insider Trading History at Verona Pharma PLC American Depositary Share

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2025Sell10,808$13.14$142,017.1279,776View SEC Filing Icon  
See Full Table

Kenneth Cunningham Buying and Selling Activity at Verona Pharma PLC American Depositary Share

This chart shows Kenneth Cunningham's buying and selling at Verona Pharma PLC American Depositary Share by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Verona Pharma PLC American Depositary Share Company Overview

Verona Pharma PLC American Depositary Share logo
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: $106.91
Low: $106.91
High: $106.91

50 Day Range

MA: $106.65
Low: $105.91
High: $106.95

2 Week Range

Now: $106.91
Low: $31.09
High: $106.93

Volume

N/A

Average Volume

1,457,608 shs

Market Capitalization

$9.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05